Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers

Bibliographic Details
Title: Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers
Authors: Jin Ho Choi, Hwanhee Park, Joo Kyung Park, Jong Kyun Lee, Kyu Taek Lee, Kwang Hyuck Lee
Source: Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Publisher Information: SAGE Publishing, 2024.
Publication Year: 2024
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Background: A regimen of gemcitabine, cisplatin, and nab-paclitaxel (GPA) has shown promising results in patients with advanced biliary tract cancer (aBTC). Objectives: This study aimed to evaluate the benefit of GPA compared to a regimen of gemcitabine plus cisplatin (GP) in patients with aBTC. Design: Retrospective study. Methods: Patients with aBTC who received first-line chemotherapy with GPA or GP regimen at the Samsung Medical Center between July 2020 and June 2022 were included. The primary endpoint was progression-free survival (PFS). Results: In all, 37 patients were treated with GPA and 43 patients with GP. The GPA group showed significantly longer median PFS [12.0 months (95% CI, 7.2–16.8)] compared to the GP group [5.5 months (95% CI, 3.7–7.4; p = 0.007)]. The median overall survival (OS) was also longer in the GPA group [18.7 months (95% CI, 13.7–23.7)] than in the GP group [10.7 months (95% CI, 1.5–19.9); p = 0.021]. First-line chemotherapy with GPA was associated with longer PFS, while metastatic disease at initial diagnosis and post-treatment increase in CA 19-9 level were associated with worse PFS. Conclusion: The GPA regimen improved the PFS of patients with aBTC compared to the GP regimen but showed no significant benefit in terms of OS after adjusting for confounding variables. Further large-scale studies are required to establish optimal indications for GPA.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1758-8359
17588359
Relation: https://doaj.org/toc/1758-8359
DOI: 10.1177/17588359231225045
Access URL: https://doaj.org/article/b893d6a07f724bd88b7ecd534a0b554a
Accession Number: edsdoj.b893d6a07f724bd88b7ecd534a0b554a
Database: Directory of Open Access Journals
More Details
ISSN:17588359
DOI:10.1177/17588359231225045
Published in:Therapeutic Advances in Medical Oncology
Language:English